<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03811080</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012302</org_study_id>
    <nct_id>NCT03811080</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease</brief_title>
  <official_title>A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-Group, Phase 3, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the superiority of efficacy of DWP14012, once
      daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, double blind, randomized, placebo-controlled, parallel-group, phase 3
      study. Subjects will be randomly assigned to one of the three treatment groups (DWP14012 A mg
      or DWP14012 B mg or placebo).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Percentage of patients with complete resolution of major symptoms (heartburn and acid regurgitation) at 4-week</measure>
    <time_frame>4 week</time_frame>
    <description>defined as no episodes of symptom during the last 7 days of treatment, using Reflux Disease Questionnaire(RDQ)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reflux disease symptom assessment using RDQ(Reflux disease questionnaire)</measure>
    <time_frame>2 week, 4 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reflux disease symptom assessment using Subject diary</measure>
    <time_frame>4 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment using PAGI-QoL</measure>
    <time_frame>4 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>4 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">327</enrollment>
  <condition>Non-Erosive Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>DWP14012 A mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 A mg, tablet, once daily, oral administration for up to 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP14012 B mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 B mg, tablet, once daily, oral administration for up to 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, tablet, once daily, oral administration for up to 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 A mg</intervention_name>
    <description>The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.</description>
    <arm_group_label>DWP14012 A mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 B mg</intervention_name>
    <description>The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.</description>
    <arm_group_label>DWP14012 B mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged between 20 and 75 years

          2. Subjects who were not observed mucosal break according to the LA classification(LA
             grade) on the EGD

          3. Subjects who had experienced major symptom within 3 months

          4. Subjects who had experienced major symptom within 7 days before randomization. Entry
             into study also required that patients had experienced at least mild symptoms on at
             least 2 days/week or at least moderate symptoms on at least 1 day/week

          5. Subjects who is able to understand and follow the instructions

          6. Subjects who voluntarily signed written informed consent form

        Exclusion Criteria:

          1. Subjects who have Barrett's esophagus, gastroesophageal varices, esophageal stenosis,
             ulcer stenosis, active gastric ulcer, gastrointestinal bleeding or malignant tumor
             confirmed by endoscopy

          2. Subjects who have erosive esophagitis, acute upper gastrointestinal bleeding, gastric
             ulcers or duodenal ulcers within 2 months before Visit 1

          3. Subjects diagnosed with functional dyspepsia, primary esophageal motility disorder,
             IBS, IBD in the last 3 months

          4. Subjects who have a history of gastric acid suppression surgery or gastroesophageal
             surgery

          5. Subjects with Zollinger-Ellison syndrome

          6. Subjects with eosinophilic esophagitis

          7. Subjects with clinically significant liver, kidney, nervous system, respiratory,
             endocrine, hematologic, cardiovascular, urinary system disease .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daewoong Pharmaceutical Co. LTD.</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ohyoung Lee</last_name>
      <phone>82-2-2290-9652</phone>
      <email>irb@hyumc.com</email>
    </contact>
    <investigator>
      <last_name>Ohoyoung Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2019</study_first_posted>
  <last_update_submitted>June 23, 2019</last_update_submitted>
  <last_update_submitted_qc>June 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

